Sign In
Buy ELAN
Elanco Animal Health Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $0.346 |
| EPS actual | $0.400 |
| EPS Surprise | 15.74% |
| Revenue estimate | 1.277B |
| Revenue actual | 1.371B |
| Revenue Surprise | 7.35% |
| Release date | Feb 24, 2026 |
| EPS estimate | $0.110 |
| EPS actual | $0.130 |
| EPS Surprise | 18.18% |
| Revenue estimate | 1.093B |
| Revenue actual | 1.144B |
| Revenue Surprise | 4.67% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.130 |
| EPS actual | $0.190 |
| EPS Surprise | 46.15% |
| Revenue estimate | 1.092B |
| Revenue actual | 1.137B |
| Revenue Surprise | 4.14% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.200 |
| EPS actual | $0.260 |
| EPS Surprise | 30.00% |
| Revenue estimate | 1.089B |
| Revenue actual | 1.241B |
| Revenue Surprise | 13.91% |
Last 4 Quarters for Elanco Animal Health
Below you can see how ELAN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $16.48 |
| EPS estimate | $0.200 |
| EPS actual | $0.260 |
| EPS surprise | 30.00% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $13.79 |
| Aug 04, 2025 | $14.07 |
| Aug 05, 2025 | $14.20 |
| Aug 06, 2025 | $13.95 |
| Aug 07, 2025 | $16.48 |
| Aug 08, 2025 | $16.67 |
| Aug 11, 2025 | $17.10 |
| Aug 12, 2025 | $17.43 |
| Aug 13, 2025 | $17.81 |
| 4 days before | 19.51% |
| 4 days after | 8.07% |
| On release day | 1.15% |
| Change in period | 29.15% |
| Release date | Nov 05, 2025 |
| Price on release | $21.60 |
| EPS estimate | $0.130 |
| EPS actual | $0.190 |
| EPS surprise | 46.15% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $22.57 |
| Oct 31, 2025 | $22.15 |
| Nov 03, 2025 | $22.85 |
| Nov 04, 2025 | $22.50 |
| Nov 05, 2025 | $21.60 |
| Nov 06, 2025 | $21.52 |
| Nov 07, 2025 | $21.49 |
| Nov 10, 2025 | $22.26 |
| Nov 11, 2025 | $22.86 |
| 4 days before | -4.30% |
| 4 days after | 5.83% |
| On release day | -0.370% |
| Change in period | 1.28% |
| Release date | Feb 24, 2026 |
| Price on release | $26.38 |
| EPS estimate | $0.110 |
| EPS actual | $0.130 |
| EPS surprise | 18.18% |
| Date | Price |
|---|---|
| Feb 18, 2026 | $24.78 |
| Feb 19, 2026 | $25.20 |
| Feb 20, 2026 | $24.98 |
| Feb 23, 2026 | $24.75 |
| Feb 24, 2026 | $26.38 |
| Feb 25, 2026 | $26.84 |
| Feb 26, 2026 | $26.19 |
| Feb 27, 2026 | $26.40 |
| Mar 02, 2026 | $26.09 |
| 4 days before | 6.46% |
| 4 days after | -1.10% |
| On release day | 1.74% |
| Change in period | 5.29% |
| Release date | May 06, 2026 |
| Price on release | $26.16 |
| EPS estimate | $0.346 |
| EPS actual | $0.400 |
| EPS surprise | 15.74% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $22.37 |
| May 01, 2026 | $22.51 |
| May 04, 2026 | $22.51 |
| May 05, 2026 | $23.00 |
| May 06, 2026 | $26.16 |
| May 07, 2026 | $24.01 |
| May 08, 2026 | $23.65 |
| May 11, 2026 | $21.72 |
| May 12, 2026 | $21.43 |
| 4 days before | 16.94% |
| 4 days after | -18.08% |
| On release day | -8.24% |
| Change in period | -4.20% |
Elanco Animal Health Earnings Call Transcript Summary of Q1 2026
Elanco reported a strong Q1 2026 with 10% organic constant-currency revenue growth driven by both price (+2%) and volume (+8%) across all geographies and species. Key commercial highlights include rapid adoption and market-share gains for innovation portfolio "Big 6" products—notably Zenrelia (now blockbuster on a trailing four-quarter basis), Credelio Quattro, AdTab and the forthcoming Befrena launch—leading management to raise 2026 innovation revenue guidance to $1.2 billion and to increase full-year organic growth guidance to 5%–7%. Adjusted EBITDA and adjusted EPS beat guidance for the quarter, enabling a modest raise to adjusted EBITDA guidance ($975M–$1.005B) and adjusted EPS ($1.03–$1.09). Gross margin was slightly down in the quarter due to inventory cost flow-through and mix effects, but management expects meaningful margin expansion in H2 as inventory headwinds abate and higher-margin U.S. Pet Health accelerates. Leverage improved to 3.5x net debt at quarter end; management now expects year-end net leverage of 3.0–3.2x with a path below 3x in 2027. Elanco continues to prioritize deleveraging and reinvestment in high-ROI product launches, while pursuing productivity savings via the Elanco Ascend program (automation/AI initiatives and 5,000+ projects logged) to drive long-term margin expansion and free cash flow generation.
